Professor Rubinsztein is a leader in the field of neurodegenerative disease and autophagy.
BERLIN/LONDON, 07 February 2020 - Aladdin Healthcare Technologies SE (“Aladdin”, ISIN: DE000A12ULL2), today announces that Professor David C. Rubinsztein has been appointed as Chief Scientific Advisor. David is the Deputy Director of the Cambridge Institute of Medical Research, Professor of Molecular Neurogenetics at the University of Cambridge and UK Dementia Research Institute Professor. His research interests are in autophagy and neurodegeneration.
He is a Fellow of the Royal Society and the Academy of Medical Sciences. David is a highly cited researcher from Clarivate Analytics and Thomson Reuters. He has published more than 390 papers, including studies in well-known international journals like Nature and Cell, with more than 75,000 Google Scholar citations.
“I am delighted to welcome Professor David C. Rubinsztein as Chief Scientific Advisor,” said Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE. “As a leader within his industry, he will bring enormous experience and expertise in the fields of neurodegenerative disease and advise the product direction of our company. Moreover, David will help with the validation process of the various prototypes on Aladdin’s ‘Early Diagnosis Platform’. He will also lead the development of Aladdin’s neurodegenerative disease-centric knowledge graph, which aims to achieve disease pathway discovery, target discovery and novel biomarker discovery.
Wade Menpes-Smith (Chairman)
About Aladdin Healthcare Technologies SE
Website Link: www.aladdinid.com
TICKER SYMBOL: NMI
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related disease including a significant focus on Alzheimer’s disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including genomic, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical companies to speed up drug development, clinical trials and predict outcomes more accurately.